Overview

* Cardlytics ( CDLX ) Q2 revenue declines 9% yr/yr, just missing analyst expectations

* Adjusted EBITDA turns positive, improving from negative in prior year

* Monthly qualified users increase 19% yr/yr, indicating consumer base growth

Outlook

* Cardlytics expects Q3 2025 revenue of $52.2 mln to $58.2 mln

* Company anticipates Q3 2025 billings of $87.0 mln to $95.0 mln

* Cardlytics sees Q3 2025 adjusted EBITDA between $(2.3) mln and $2.7 mln

* Company forecasts Q3 2025 adjusted contribution of $30.3 mln to $34.3 mln

Result Drivers

* DIVERSIFICATION EFFORTS - CEO Amit Gupta cites strategic shifts in diversification as key to navigating economic headwinds

* USER GROWTH - 19% increase in monthly qualified users indicates expanding consumer base

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Miss $63.25 $64 mln

Revenue mln (4

Analysts

)

Q2 EPS -$0.18

Q2 Net -$9.28

Income mln

Q2 $104.05

Billings mln

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 5 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the software peer group is "buy."

* Wall Street's median 12-month price target for Cardlytics Inc ( CDLX ) is $2.50, about 26.4% above its August 5 closing price of $1.84

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)